Overview

Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
To test the feasibility of theranostic targeting the PSMA receptor in STS patients by Ga-68-PSMA-11 PET/CT and Lu-177-ITG-PSMA-1 treat-ment with special emphasis on vascular disruption using a translational approach.
Phase:
Phase 1
Details
Lead Sponsor:
John O. Prior
Treatments:
Gallium 68 PSMA-11